Sumitomo Pharma Management

Management criteria checks 2/4

Sumitomo Pharma's CEO is Hiroshi Nomura, appointed in Apr 2018, has a tenure of 6.17 years. directly owns 0.018% of the company’s shares, worth ¥24.92M. The average tenure of the management team and the board of directors is 3.2 years and 5.5 years respectively.

Key information

Hiroshi Nomura

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	6.2yrs
CEO ownership	0.02%
Management average tenure	3.2yrs
Board average tenure	5.5yrs

Recent management updates

Recent updates

Is Sumitomo Pharma Co., Ltd. (TSE:4506) Trading At A 34% Discount?

May 13

Market Cool On Sumitomo Pharma Co., Ltd.'s (TSE:4506) Revenues

Apr 17

CEO Compensation Analysis

How has Hiroshi Nomura's remuneration changed compared to Sumitomo Pharma's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-JP¥315b
Dec 31 2023	n/a	n/a	-JP¥174b
Sep 30 2023	n/a	n/a	-JP¥135b
Jun 30 2023	n/a	n/a	-JP¥144b
Mar 31 2023	n/a	n/a	-JP¥75b
Dec 31 2022	n/a	n/a	-JP¥8b
Sep 30 2022	n/a	n/a	JP¥13b
Jun 30 2022	n/a	n/a	JP¥83b
Mar 31 2022	n/a	n/a	JP¥56b
Dec 31 2021	n/a	n/a	JP¥32b
Sep 30 2021	n/a	n/a	JP¥55b
Jun 30 2021	n/a	n/a	JP¥43b
Mar 31 2021	JP¥101m	JP¥83m	JP¥56b

Compensation vs Market: Insufficient data to establish whether Hiroshi's total compensation is reasonable compared to companies of similar size in the JP market.

Compensation vs Earnings: Insufficient data to compare Hiroshi's compensation with company performance.

CEO

Hiroshi Nomura (67 yo)

6.2yrs

Tenure

JP¥101,000,000

Compensation

Mr. Hiroshi Nomura served as Director of Roivant Sciences Ltd. since September 16, 2022 until August 31, 2023. He has been Chief Executive Officer and President of Sumitomo Pharma Co., Ltd.(Formerly Sumit...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Hiroshi Nomura	CEO, President & Representative Director	6.2yrs	JP¥101.00m	0.018% ¥ 24.9m
Toru Kimura	Sr. Mngg Exec. Off. of Glo. Crprate Stgy	8.4yrs	no data	0.013% ¥ 18.3m
Hiroyuki Baba	Mngg Exec. Officer of Global Data Design	7.2yrs	no data	0.0015% ¥ 2.1m
Naoki Noguchi	Executive Officer of Corporate Governance & Communications	2.2yrs	no data	no data
Atsuko Higuchi	Managing Executive Officer of External Affairs	no data	no data	no data
Yoshiharu Ikeda	Managing Executive Officer of Drug Research Division	4yrs	no data	0.0038% ¥ 5.3m
Koichi Kozuki	E.O. of R. Aff.	1.4yrs	no data	no data
Shigeyuki Nishinaka	Managing Executive Officer of Business Development & Management and Director	7.2yrs	no data	0.0020% ¥ 2.8m
Isao Shimizu	Executive Officer	1.4yrs	no data	no data
Kenji Ueno	Executive Officer	1.4yrs	no data	no data
Hideyuki Harada	Managing Exe. Officer of Tech. R&D Div.	3.2yrs	no data	no data
Adele M. Gulfo	Executive Officer & CEO of Biopharma Commercial Unit of Sumitomo Pharma America	1.4yrs	no data	no data

3.2yrs

Average Tenure

64.5yo

Average Age

Experienced Management: 4506's management team is considered experienced (3.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Hiroshi Nomura	CEO, President & Representative Director	12yrs	JP¥101.00m	0.018% ¥ 24.9m
Toru Kimura	Sr. Mngg Exec. Off. of Glo. Crprate Stgy	8yrs	no data	0.013% ¥ 18.3m
Hiroyuki Baba	Mngg Exec. Officer of Global Data Design	2yrs	no data	0.0015% ¥ 2.1m
Yoshiharu Ikeda	Managing Executive Officer of Drug Research Division	4yrs	no data	0.0038% ¥ 5.3m
Shigeyuki Nishinaka	Managing Executive Officer of Business Development & Management and Director	10.2yrs	no data	0.0020% ¥ 2.8m
Saeko Arai	Independent Outside Director	6yrs	no data	no data
Minoru Usui	Independent Outside Director	3yrs	no data	no data
Nobuhiro Endo	Independent Outside Director	5yrs	no data	no data
Takashi Kutsunai	Full-Time Audit & Supervisory Board Member	6yrs	no data	0.0053% ¥ 7.4m
Yoshio Iteya	Outside Audit & Supervisory Board Member	6yrs	no data	no data
Hisayoshi Kashima	Full-Time Audit & Supervisory Board Member	less than a year	no data	0.0020% ¥ 2.8m
Koji Fujimoto	Independent Outside Director	2yrs	no data	no data

5.5yrs

Average Tenure

66yo

Average Age

Experienced Board: 4506's board of directors are considered experienced (5.5 years average tenure).

Sumitomo Pharma Management

Management criteria checks 2/4

Key information

Recent management updates

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 25, 2024

Sumitomo Pharma Co., Ltd. Announces Executive Changes

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 27, 2023

Less than half of directors are independent

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 23, 2022

Less than half of directors are independent

Recent updates

Consensus EPS estimates upgraded to JP¥77.85 loss

Consensus EPS estimates upgraded to JP¥103 loss

Sumitomo Pharma Co., Ltd. to Report Q1, 2025 Results on Jul 31, 2024

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 25, 2024

Full year 2024 earnings: EPS misses analyst expectations

Is Sumitomo Pharma Co., Ltd. (TSE:4506) Trading At A 34% Discount?

Price target decreased by 18% to JP¥334

Consensus EPS estimates fall by 21%

Market Cool On Sumitomo Pharma Co., Ltd.'s (TSE:4506) Revenues

Sumitomo Pharma Co., Ltd. to Report Fiscal Year 2024 Results on May 14, 2024

Price target decreased by 10% to JP¥413

Consensus EPS estimates fall by 24%

Consensus EPS estimates fall by 24%

Consensus EPS estimates fall by 24%

Price target decreased by 7.8% to JP¥442

Consensus EPS estimates fall by 23%

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

New major risk - Share price stability

Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

Sumitomo Pharma Co., Ltd. to Report Q3, 2024 Results on Jan 31, 2024

European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of Endometriosis

Gedeon Richter Plc., Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH Receives European Commission grant for Commercialisation of RYEQO®

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal Year Ending March 31, 2024

Price target decreased by 9.3% to JP¥510

Sumitomo Pharma Announces Positive Topline Results from Phase 3 Clinical Studies Evaluating Vibegron in Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia

Consensus EPS estimates fall by 10%

Consensus EPS estimates fall by 15%

Price target decreased by 11% to JP¥630

Sumitomo Pharma Co., Ltd. to Report Q2, 2024 Results on Oct 31, 2023

Sumitomo Pharma Co., Ltd. (TSE:4506) acquired Assets and rights related lefamulin in China, Hong Kong, Macau and Taiwan from Nabriva Therapeutics plc (OTCPK:NBRV.F), Nabriva Therapeutics US, Inc, Nabriva Therapeutics GmbH and Nabriva Therapeutics Ireland Dac for $15 million.

First quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Share price stability

Sumitomo Pharma and Otsuka Announce Topline Results from Phase 3 Diamond 1 and Diamond 2 Clinical Studies Evaluating Ulotaront in Schizophrenia

Consensus EPS estimates fall by 14%

Sumitomo Pharma Co., Ltd. Announces Executive Changes

Sumitomo Pharma Co., Ltd. to Report Q1, 2024 Results on Jul 31, 2023

Revolka Ltd. Announces Milestone Achievement in the Collaborative Research with Sumitomo Pharma Co., Ltd

HEALIOS K.K. and Sumitomo Pharma Co. Ltd. Announces Start of Phase 1/2 Study in RPE Tear Using RPE Cells Derived from Allogeneic iPS Cells (HLCR011)

Sumitomo Pharma Oncology, Inc. Presents Updated Preliminary Data from Phase 1/2 Clinical Study Evaluating Investigational Agent TP-3654 in Patients with Myelofibrosis at European Hematology Association 2023 Hybrid Congress

Consensus EPS estimates fall by 17%

Price target decreased by 10% to JP¥811

Price target decreased by 7.2% to JP¥883

Consensus EPS estimates fall by 26%, revenue upgraded

Sumitomo Pharma Co., Ltd. Announces Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023

Full year 2023 earnings: EPS misses analyst expectations

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 27, 2023

Consensus EPS estimates upgraded to JP¥35.42 loss

Consensus EPS estimates upgraded to JP¥35.42 loss

Upcoming dividend of JP¥7.00 per share at 3.5% yield

Consensus estimates of losses per share improve by 85%

Consensus EPS estimates have been downgraded.

Sumitomo Pharma Co., Ltd. to Report Fiscal Year 2023 Results on May 15, 2023

Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Third quarter 2023 earnings released: JP¥28.24 loss per share (vs JP¥24.94 profit in 3Q 2022)

Mitsui & Co., Ltd. (TSE:8031) agreed to acquire Sumitomo Pharma Animal Health Co., Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506).

Sumitomo Pharma Co., Ltd. to Report Q3, 2023 Results on Jan 31, 2023

MediPal Holdings Corporation (TSE:7459) entered into a Share Purchase agreement to acquire Sumitomo Pharma FOOD & CHEMICAL Co., LTD. from Sumitomo Pharma Co., Ltd. (TSE:4506).

Consensus forecasts updated

Less than half of directors are independent

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Sumitomo Pharma Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Consensus forecasts updated

Now 20% undervalued after recent price drop

Sumitomo Pharma Co., Ltd. Provides Impairment Loss Guidance for the Second Quarter of the Fiscal Year Ending March 31, 2023

Upcoming dividend of JP¥14.00 per share

Now 21% undervalued

Sumitomo Pharma Co., Ltd. to Report Q2, 2023 Results on Oct 31, 2022

First quarter 2023 earnings: EPS and revenues exceed analyst expectations